Caribou Biosciences, Inc.
Company Stats
- Market Cap
- $136.2M
- as of Sep 30, 2026
- Shares Outstanding
- 107.2M
- Free Float
- 88.6%
Income Statement
- Revenue
- $11.2M
- Operating Income
- -$148.3M
- Net Income
- -$148.1M
- EBITDA
- -$144.7M
- Non-cash Impairment
- $12.2M
- Revenue Growth, 3Y
- -7.0%
- FCF Margin, 3Y Avg
- -914.3%
- FCF Margin, Worst Year
- -1431.7%
Cash Flow
- Free Cash Flow
- -$112.4M
- FCF Yield
- -82.5%
- Owner FCF Yield
- -91.8%
Balance Sheet
- Cash & Equivalents
- $12.4M
Returns & Capital
- SBC, 3Y Avg
- $14.4M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $11.2M | -$112.4M | -1006.8% |
| FY2024 | $10.0M | -$143.1M | -1431.7% |
| FY2023 | $34.5M | -$104.9M | -304.3% |
| FY2022 | $13.9M | -$97.4M | -703.3% |
| FY2021 | $9.6M | -$34.6M | -360.9% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 1, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges